RxDoctor Payments Data

Chanh Nguyen, MD

Internal Medicine · Conroe, TXNPI 1932366135

Payments from drug & device makers

$1,744in general payments, 2019–2025

Across 88 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$299
  • Pfizer$157
  • Amgen$155
  • AbbVie$154
  • Exact Sciences$152
  • Novo Nordisk$126
  • plus $701 from 14 others

What the payments were for

  • Food & beverage$1,67996%
  • Education$654%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,744 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$142,984
Medicare patients
256
Services billed
3,697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide119$134,433
EliquisApixaban76$91,769
JanuviaSitagliptin Phosphate57$84,788
MounjaroTirzepatide46$68,509
JardianceEmpagliflozin39$55,216
TrulicityDulaglutide29$54,437
XareltoRivaroxaban33$38,520
Tresiba Flextouch U-100Insulin Degludec56$37,686
FarxigaDapagliflozin Propanediol34$34,441
LinzessLinaclotide20$24,380
Tresiba Flextouch U-200Insulin Degludec11$21,098
Levemir FlexpenInsulin Detemir61$20,935
MyrbetriqMirabegron15$19,329
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen671$19,084
Repatha SureclickEvolocumab14$15,061

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$126$134,433119 claims
Lilly USA, LLCMounjaro, Trulicity$299$122,94675 claims
PfizerEliquis$157$91,76976 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat$67$69,17766 claims
AstraZenecaFarxiga, Symbicort$49$37,33246 claims
AbbVieLinzess$154$24,38020 claims
Astellas Pharma US IncMyrbetriq$105$19,32915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Conroe

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →